Medigene has applied its extensive know-how relating to T cells and their control to establish three innovative platform technologies centered on the T cell as the most potent player in the immune system to combat cancer.
Our three complementary platforms are designed to treat multiple types of cancer and different stages of disease, so that optimally tailored T-cell responses can be provided to individual patients according to their medical needs:
T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy provide potential treatments for patients with large tumor burdens.
Dendritic cell (DC) vaccines are intended for the treatment of low tumor burdens such as minimal residual disease or for use in combination therapies.
T-cell-specific monoclonal antibodies (TABS) identify T cells based on their unique T-cell receptors.
Medigene focuses on the development of living immunotherapies to treat different forms of cancer. Living immunotherapies are treatments based on living cells made from a patient’s own immune cells.
Lochhamer Str. 11
Phone: +49 89 2000330
Fax: +49 89 2000332920
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.
Click here if you notice an image that violates copyright or privacy rights.